KRAS G12A

Clinical trials for KRAS G12A explained in plain language.

Never miss a new study

Get alerted when new KRAS G12A trials appear

Sign up with your email to follow new studies for KRAS G12A, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 3 Not yet finished but already full! 1

New immunotherapy targets tough pancreatic cancers in early trial

Disease control Ongoing

This early-phase trial tests an experimental immunotherapy called ELI-002 7P in people with pancreatic or other solid tumors that have specific KRAS or NRAS gene mutations. The treatment aims to train the immune system to attack cancer cells. About 158 participants will receive t…

Matched conditions: KRAS G12A

Phase: PHASE1, PHASE2 • Sponsor: Elicio Therapeutics • Aim: Disease control

Last updated Jun 15, 2026 18:56 UTC

KRAS G12A

Get alerted when new KRAS G12A trials appear

New immunotherapy targets tough pancreatic cancers in early trial